S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners

RVL Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RVLP)

$0.0037
0.00 (0.00%)
(As of 11/27/2023 ET)
Compare
Today's Range
$0.0027
$0.0044
50-Day Range
$0.00
$0.19
52-Week Range
$0.03
$1.91
Volume
2.77 million shs
Average Volume
N/A
Market Capitalization
$406,646.50
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50

RVL Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
68,393.2% Upside
$2.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$348,059 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.46) to ($0.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars


RVLP stock logo

About RVL Pharmaceuticals Stock (NASDAQ:RVLP)

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

RVLP Stock Price History

RVLP Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
RVL Pharmaceuticals Subsidiaries File for Bankruptcy
Why Is RVL Pharmaceuticals (RVLP) Stock Up 28% Today?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
RVL Pharmaceuticals (RVLP) Gets a Buy from H.C. Wainwright
RVLP: Second Quarter Results
Q2 2023 RVL Pharmaceuticals PLC Earnings Call
RVLP: First Quarter Results
See More Headlines
Receive RVLP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RVL Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/20/2023
Today
11/28/2023
Next Earnings (Estimated)
11/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RVLP
Fax
N/A
Employees
125
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.50
High Stock Price Target
$3.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+68,393.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-51,690,000.00
Net Margins
-184.91%
Pretax Margin
-185.66%

Debt

Sales & Book Value

Annual Sales
$49.72 million
Book Value
$0.51 per share

Miscellaneous

Free Float
106,504,000
Market Cap
$406,646.50
Optionable
Optionable
Beta
1.32
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Brian A. Markison (Age 64)
    Chairman, President, CEO & Principal Financial Officer
    Comp: $525k
  • Mr. James D. Schaub (Age 41)
    Executive VP & COO
    Comp: $367.2k
  • Mr. Christopher A. Klein (Age 58)
    General Counsel & Secretary
    Comp: $367.2k
  • Mr. Michael J. DePetris (Age 46)
    Principal Accounting Officer
  • Mr. Jarret Miller
    Executive Vice President of Human Resources














RVLP Stock Analysis - Frequently Asked Questions

Should I buy or sell RVL Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RVL Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RVLP shares.
View RVLP analyst ratings
or view top-rated stocks.

What is RVL Pharmaceuticals' stock price target for 2024?

1 equities research analysts have issued 1-year price objectives for RVL Pharmaceuticals' shares. Their RVLP share price targets range from $2.00 to $3.00. On average, they predict the company's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 68,393.2% from the stock's current price.
View analysts price targets for RVLP
or view top-rated stocks among Wall Street analysts.

How have RVLP shares performed in 2023?

RVL Pharmaceuticals' stock was trading at $1.12 at the beginning of 2023. Since then, RVLP shares have decreased by 99.7% and is now trading at $0.0037.
View the best growth stocks for 2023 here
.

When is RVL Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 30th 2023.
View our RVLP earnings forecast
.

How were RVL Pharmaceuticals' earnings last quarter?

RVL Pharmaceuticals plc (NASDAQ:RVLP) posted its quarterly earnings data on Monday, March, 20th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.03. The business had revenue of $9.81 million for the quarter, compared to the consensus estimate of $12.10 million. RVL Pharmaceuticals had a negative trailing twelve-month return on equity of 130.22% and a negative net margin of 184.91%. During the same period last year, the company earned ($0.26) earnings per share.

Who are RVL Pharmaceuticals' major shareholders?

RVL Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Foundation Harsaul and Ltd Altchem.
View institutional ownership trends
.

How do I buy shares of RVL Pharmaceuticals?

Shares of RVLP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:RVLP) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -